Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 147 Melanoma 122 Breast Neoplasms 98 Squamous Cell Carcinoma of Head and Neck 96 Triple Negative Breast Neoplasms 85 Lung Neoplasms 64 Neoplasm Metastasis 53 Carcinoma, Renal Cell 49 Neoplasms 46 Head and Neck Neoplasms 46 Colorectal Neoplasms 41 Ovarian Neoplasms 38 Carcinoma, Transitional Cell 37 Carcinoma, Hepatocellular 36 Pancreatic Neoplasms 35 Urinary Bladder Neoplasms 34 Recurrence 33 Stomach Neoplasms 32 Glioblastoma 30 Brain Neoplasms 28 Sarcoma 26 Endometrial Neoplasms 25 Prostatic Neoplasms 23 Hodgkin Disease 22 Uterine Cervical Neoplasms 19 Fallopian Tube Neoplasms 19 Carcinoma, Squamous Cell 19 Esophageal Squamous Cell Carcinoma 17 Adenocarcinoma 17 Multiple Myeloma 16

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urothelial Bladder Carcinoma × pembrolizumab × Clear all

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡